Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of sacituzumab govitecan versus physician's choice chemotherapy in previously treated endometrial cancer
MOH_2024-12-16_013799Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in endometrial cancer (EC) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Progression-free survival and Overall survival. Started Nov 2024; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2024-12-16_013799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-12-16_013799.